Kornimate/medical-research-clean huggingface dataset:
a study to assess absolute bioavailability of aducanumab in healthy volunteers

Conditions: Healthy Volunteers

Summary: the primary objective of this study is to evaluate the absolute bioavailability of a single, fixed subcutaneous (sc) dose of aducanumab compared with a single weight-based intravenous (iv) dose of aducanumab in healthy volunteers. the secondary objectives of this study are to assess the safety and tolerability of aducanumab administered sc in healthy volunteers and to characterize additional pharmacokinetic (pk) parameters of a single, fixed sc dose of aducanumab and a weight-based iv dose of aducanumab in healthy volunteers.


Eligibility criteria:
key inclusion criteria: * have a body mass index (bmi) between 18 and 30 kilograms per meter square (kg/m\^2), inclusive. * have a negative test result for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) on day -1. key exclusion criteria: * history of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the investigator. * history of severe allergic, anaphylactic, or systemic hypersensitivity reactions, or of any allergic reactions that in the opinion of the investigator are likely to be exacerbated by aducanumab, the excipients contained in the formulation, and if appropriate, and diagnostic agents to be administered during the study. * chronic, recurrent, or serious infection (e.g., pneumonia, septicemia), as determined by the investigator, within 90 days prior to screening or between screening and day -1. * any immunization or vaccination given within 10 days prior to day 1 and for 10 days after day 1. * current enrollment in any other drug, biological, device, or clinical study, or treatment with an investigational drug or approved therapy for investigational use within 30 days prior to day -1, or 5 half-lives, whichever is longer. * prior exposure to the study treatment or previous participation in this study or previous studies with aducanumab. * mini mental state examination (mmse) score of \<27 at screening. note: other protocol defined inclusion/exclusion criteria may apply.
late ltp-like plasticity effects of tdcs in chronic stroke patients

Conditions: Stroke; Hemiparesis

Summary: rationale: about 80% of stroke patients suffer motor impairments, but current therapies have limited effects on motor recovery. therefore, investigating new potential therapeutic approaches is crucial. transcranial direct current stimulation (tdcs) is a form of non-invasive electrical stimulation where a weak current is applied through electrodes over the scalp. this stimulation is known to (1) induce changes in neuronal excitability -which can last up to one day with late ltp-like plasticity protocols- in a polarity and site-specific manner, and (2) facilitate motor learning and stroke recovery. however, it is unknown how the motor cortex excitability changes that follow tdcs relate to the increase in motor learning and recovery potential. the currently upheld hypothesis is that motor learning needs to be synchronized in time with electrical stimulation (paired stimulation), but recent results from our lab suggest that tdcs also increases skill learning after stimulation has ended (unpaired stimulation). if this is true, tdcs has a much larger therapeutic window and is a more valuable clinical tool than currently believed. therefore, the investigators want to investigate how late ltp-like plasticity tdcs affects the increase in skill learning normally seen with tdcs when applied 24 hours before training. the outcome of this study can provide important guidelines on effective motor therapy during stroke rehabilitation. objective: identify the effect of late ltp-like plasticity tdcs in chronic stroke patients on skill learning 24 hours later. study design: double-blinded, randomized between-subjects trials. study population: chronic stroke patients. main study parameters/endpoints: the main objective of the study is to determine the effect of late ltp-like plasticity tdcs on skill learning 24 hours later. as a motor learning paradigm, the investigators will use a circuit tracking task which chronic stroke patients perform better if tdcs is applied concurrently. during this task, patients have to trace a cursor over a circuit as fast and accurately as possible by moving a computer mouse. skill will be quantified by calculating a combined speed/ accuracy score and skill improvement compared to baseline (li; the learning index) will be compared between the sham, conventional unpaired tdcs, conventional paired tdcs groups and the late ltp-like plasticity tdcs groups.


Eligibility criteria:
inclusion criteria: * chronic (\> 6 months) stroke patient * aged 18-79 years * motor deficit in the upper limb due to the stroke exclusion criteria: * absence of recordable meps from the adm after tms * absence of voluntary movement (fugl-meyer \< iii) * head injury or the presence of intracranial metal or intracranial lesions * history of cranial irradiation * history of epilepsy * presence of a pacemaker * taking anticonvulsant or neuroleptic medication * substance abuse * inability to understand instructions * history of psychiatric disorders
lifestyle modification using an app in osa

Conditions: Obstructive Sleep Apnea; Obesity

Summary: this study aimed to investigate the effects of a mobile phone app linked to hospital electronic medical record (emr) system on weight reduction and obstructive sleep apnea (osa). adults aged \> 20 years with witnessed snoring or sleep apnea from a sleep clinic of a tertiary center were prospectively enrolled, and the participats were randomized into app user and control groups. the mobile app was designed to collect daily lifestyle data by wearing a wrist activity tracker and reporting dietary intake. at the visit after 2 weeks of use, a summary of the lifestyle was displayed on the hospital emr and reviewed by both physicians and app users. further lifestyle modification was encouraged on the basis of the electronically collected data. in the control group, the lifestyle modification performed as the usual practice. all participants underwent watch pat and body mass index (bmi) measurement twice: on enrollment; and after 4-weeks follow up. changes of bmi, and parameters of sleep related breathing were analyzed.


Eligibility criteria:
inclusion criteria: ᆞ patients must agree to participate in our clinical study ᆞ patients without severe cardiopulmonary disease ᆞ patients must be with bmi \> 23 kg/m2 exclusion criteria: ᆞ patients who did not agree ᆞ patients with severe cardiopulmonary disease ᆞpatients who are under treatment using a continuous positive airway pressure device or a mandibular advancement device ᆞ patients who were pregnant
bacterial load for integra™ in operative wounds

Conditions: Wounds and Injuries

Summary: proportion of postoperative complications (infections, dehiscence, graft slough) after initial application of integra™

this is a study examining the use of integra™ for the treatment of lower extremity wounds to better understand the relationship between bacteria contamination levels and post-operative complications. wounds requiring operative application of integra™ alone or integra™ followed by a planned subsequent application of a stsg will be enrolled into this study. the tolerance of integra™ to bacterial bioburden at the time of application will be determined by observing their respective postoperative wound complications and correlating these findings with quantitative bacterial counts, qualitative culture results, and bacterial and wound protease levels at the time of integra™ alone application or integra™ followed by stsg application. patients will then be followed until complete healing has occurred or until 16 weeks, whichever comes first.

Eligibility criteria:
inclusion criteria: * male or female age 18-90. * full-thickness wounds below the knee. * patients who require, in the opinion of the investigator, operative application of integra™. * patients able and willing to comply with the study protocol. exclusion criteria: * male or female under 18 or over 90 * patients that do not have full-thickness wounds below the knee * patients who do not require, in the opinion of the investigator, operative application of integra™. * patients that are not able or willing to comply with the study protocol.

Keywords: lower extremity
hemostatic complications in hematopoietic stem cell transplantation

Conditions: Hemostatic Disorders

Summary: hemostatic disorders are common and potentially fatal complications in patients undergoing hematopoietic stem-cell transplantation (hsct). limited data exist on early diagnosis and prevention of these complications. the investigators undertook this prospective study to determine the incidence, predictor factors, specific pathogenesis, management and survival specially for patients with thrombotic and bleeding complication to better improve outcomes.

hematopoietic stem cell transplantation（hsct）is a curative treatment for a variety of malignant and refractory benign hematologic disease, but is associated with life-threatening complications in the same time, among them, hemostatic disorders are not uncommon and presenting an increasing morbidity and mortality in hsct recipients. bleeding and thrombosis, two of controversial disorders, have been posing a great threat to patients in the setting of transplantation, and early hemorrhagic complication after hcst is more frequent and subject to more concern by clinical physicians, previous studies have shown the risk of bleeding in hsct recipients is more than 10-fold higher than neoplastic patients receiving chemotherapy. meanwhile, thrombosis events, which is characterized by hepatic veno-occlusive diseases (hvod), transplantation related thrombotic microangiopathy (ta-tma), and venous thromboembolism (vte) can not be imprudently ignored with its fatal threat to patients. over the last two decades, it has been recognized that the relatively increasing incidence of bleeding and thrombotic complications correlating to the prognosis and quality of life for hsct recipients. previous studies have shown that conventional risk factors including graft-versus-host disease (gvhd), infection, thrombocytopenia, the anticoagulation therapy, damage of endothelial cell and conditioning regimen can contribute to the onset of hemostatic disorders in hsct recipients or can even exacerbate the process. nevertheless, their roles and detailed pathogenesis in the development of bleeding and thrombosis remain undefined and limited data in asian population was known about the competing risks of thrombosis and bleeding. given the current understanding of hemostatic complication and many unknown mechanisms of relation between thrombosis and hemostasis，we undertook this prospective study to determine the incidence, predictor factors, specific pathogenesis, and survival specially for patients with thrombotic and bleeding complication to better improve outcomes.

Eligibility criteria:
inclusion criteria: * 1. patients signed their informed consents are enrolled; 2. patients suffering from hematological diseases and undergoing hematopoietic stem cell transplantation. exclusion criteria: * 1. patients who have not signed their informed consents; 2. patients with previous history of platelet disorder or bleeding diathesis; 3. patients with inadequate renal function or hepatic function, or other essential organ damage.

Keywords: hematopoietic stem cell transplantation
antiretroviral-sparing concept with hiv-specific t cell precursors with high proliferative capacity (phpc)

Conditions: HIV Infection

Summary: phpc-02 is a phase ii, randomized, placebo-controlled trial designed to investigate whether therapeutic immunization during highly active antiretroviral therapy (haart) induces elevations of hiv-specific t cell precursors with high proliferative capacity (phpc) in hiv-1-infected individuals, and whether the quantity of phpc correlates with the viral load set point following analytical treatment interruption (ati). subjects will be randomized to receive either dermavir patch (8 subjects per cohort) or dermavir patch placebo (8 subjects per cohort) every four weeks for three applications while receiving maximally suppressive haart. haart will be discontinued at week 9 for an ati period of 20 weeks.

16 subjects on maximally suppressive haart were randomized to receive three doses of either dermavir or placebo immunotherapy. subjects receive three dermavir/placebo treatments over eight weeks (weeks 0, 4 and 8) while receiving haart. haart is discontinued for a 20 week ati. resumption of haart during ati is subjects experience: * a confirmed cd4+ cell decrease by \> 50% * a confirmed cd4+ cell decrease to less than 350 counts/ml * a confirmed vl increase \> 300,000 copies * emergence of cdc aids related event(s) * signs or symptoms of clinically significant immunosuppression * the subject or the subject's clinician wishes to restart haart * the subject becomes pregnant

Eligibility criteria:
main inclusion criteria: * hiv-1 infection * on a non-hydroxyurea based haart for at least one year * pre-haart cd4 nadir \> 250 cells/mm3 * pre-haart viral load \> 5,000 copies/ml * undetectable viral load for the six month period preceding the study * cd4 t-cell count \>500 cells/mm3 for the six month period preceding the study main exclusion criteria: * no skin disease * no hypersensitivity to adhesive tape or tegaderm * no history of keloid * no history of vitiligo, melasma, skin cancer * no tattoos or changes in pigment at the skin treatment sites * no autoimmune diseases * no hepatitis b, c coinfections

Keywords: hiv vaccine immune therapy dermavir treatment experienced
evaluation of the expression and prognostic role of tumor stem cell marker sox2 in odontogenic cysts and tumors

Conditions: Odontogenic Cysts; Odontogenic Tumors

Summary: the pathogenesis of odontogenic lesions remains unclear; however, a probable explanation may involve the existence of tumor stem cells (tscs), which are thought to generate both benign and malignant tumors. the preservation of stem cells during early dental development is governed by many transcription factors, including sex-determining region y (sry)-box 2 (sox-2). numerous studies observed the increased expression of sox2 in various benign and malignant tumors, as its impact on tumorigenesis varies according to tumor type. the purpose of this study is to assess the immunoexpression of the stem cell marker sox2 in diverse types of odontogenic cysts and tumors in order to identify its prognostic significance and to show if it correlates to clinicopathologic parameters of those odontogenic lesions.

forty-five surgical specimens were included in this study: 15 ameloblastomas (ab), 15 odontogenic keratocysts (okc), and 15 dentigerous cysts (dc). an immunohistochemical (ihc) study using the sox2 rabbit polyclonal antibody was done, and sox2 expression was evaluated by two methods: computer-assisted digital image analysis to measure staining surface area percentage and a semi-quantitative method for subjectively scoring percentage and intensity of sox2 staining. positive specimens were considered when the nucleus had brown staining.

Eligibility criteria:
inclusion criteria: 1. patients with benign odontogenic cysts and tumors which presented either in maxilla or mandible ( as indicated by incisional biopsies ) exclusion criteria: 1. patients with systemic diseases that absolutely contraindicate surgical procedures. 2. malignant odontogenic tumors.

Keywords: ameloblastoma odontogenic keratocyst dentigerous cyst sox2 immunohistochemistry
correlation between chronic neck pain and shoulder proprioception among patients with cervical radiculopathy

Conditions: Cervical Radiculopathy

Summary: is there correlation between cervical radiculopathy and shoulder proprioception or not?


Eligibility criteria:
inclusion criteria: * chronic neck pain with unilateral cervical radiculopathy. exclusion criteria: * has impingement syndrome ,history of instability and any systemic disease.
valsalva manœuvre in the diagnosis of left ventricular failure in chronic obstructive pulmonary disease exacerbation

Conditions: Acute Heart Failure; COPD Exacerbation

Summary: left ventricular failure (lvf) is a common cause of acute exacerbation of chronic obstructive pulmonary disease (aecopd). this association is frequently underestimated with regard to the difficulty of clinical diagnosis . the investigators expect that valsalva maneuver (vm) could be useful in this issue.


Eligibility criteria:
inclusion criteria * we included in this group, patients with a history (previous history) of copd who consulted the emergency room for an exacerbation of copd defined by a respiratory rate\> 25c/min and a ph \ 6 kpa. * this group is also divided into two groups according to clinical expert assessment and the bnp value: group1 : bnp\> 400pg/ml, group2 : bnp \<400pg / ml exclusion criteria: * we excluded from this study patients with prominent cardiac arrest * rhythm disorders including severe tachycardia arrhythmia * auricular fibrillation * hemodynamic instability requiring the use of vasoactive drugs and a contre indications of non invasive ventilation such us consciousness disorders with a glasgow score \<12/15,a swallowing disorder * a significant bronchial obstruction ,the upper airway obstruction , in upper gastrointestinal bleeding in progress, an extreme obesity and cirrhosis or cancer. * we are also excluded patients who did not cooperate and those who refused the study.

Keywords: copd left ventricular failure valsalva manoeuver
efficacy of two therapeutic exercise modalities for patients with persistent covid

Conditions: Persistent COVID-19

Summary: symptoms of long-standing sequelae and complications of covid-19, termed long covid19 or persistent covid, have been reported worldwide. however, the etiology underlying the prolonged or fluctuating symptomatology is limited and there is no uniform and widely accepted definition.patients describe persistent covid as a fluctuating disease with variable and persistent symptoms.most of the effects correspond to clinical symptoms such as fatigue, headache, arthralgias, hyposmia, gustatory sensations, etc. fatigue is the most common and prolonged symptom of persistent covid. knowledge of the pathophysiological mechanisms of fatigue in covid-19 disease, as well as the therapeutic approach, remains limited due to the relatively recent onset of this pathology. in particular, muscle strength training has been shown to improve muscle function and fatigue, not only during treatment, but also at long-term follow-up.

objective: to evaluate the effects on the perception of fatigue in patients with persistent covid, who undergo a supervised and directed therapeutic exercise program in a health center compared to a home therapeutic exercise program. methods: randomized pilot study. subjects who are included in the study will perform a therapeutic exercise program which will last 8 weeks and 2 sessions per week of 1h duration. the participants assigned to the supervised group will carry out the program at the health center, while the participants assigned to the home group will receive telematic supervision (by videoconference). both groups will be under the supervision of the assigned physiotherapist. the components that will form part of the exercise program will be: muscular strength training and continuous-variable aerobic training or hiit type with loads between 70-90% of maximum heart rate. the main variables are fatigue.

Eligibility criteria:
inclusion criteria: * adult patients diagnosed with longcovid19 or persistent covid19. * agree to participate and sign the informed consent form. exclusion criteria: * patients with comorbidities associated with having fatigue (e.g. cancer survivors, severe cardiovascular or respiratory disease prior to persistent covid). * taking medication of drugs that may interfere with the perception of fatigue. * patients with mental disorders or cognitive impairment prior to persistent covid. * patients who regularly practice intense sports (\>4h/week). * any illness that may condition understanding and compliance with the study.
a novel machine learning algorithm to predict the lewy body dementias

Conditions: Dementia

Summary: parkinson's disease dementia (pdd) and dementia with lewy bodies (dlb) are dementia syndromes that overlap in many clinical features, making their diagnosis difficult in clinical practice, particularly in advanced stages. we propose a machine learning algorithm, based only on non-invasively and easily in-the-clinic collectable predictors, to identify these disorders with a high prognostic performance.

the algorithm will be develop using dataset from two specialized memory centers, employing a sample of pdd and dlb subjects whose diagnostic follow-up is available for at least 3 years after the baseline assessment. a restricted set of information regarding clinico- demographic characteristics, 6 neuropsychological tests (mini mental, pd cognitive rating scale, brief visuospatial memory test, symbol digit written, wechsler adult intelligence scale, trail making a and b) was used as predictors. two classification algorithms, logistic regression and k-nearest neighbors (k-nns), will be investigated for their ability to predict successfully whether patients suffered from pdd or dlb.

Eligibility criteria:
inclusion criteria: the pdd group comprised of patients fulfilling the criteria for probable pdd of the movement disorders society (b) the dlb group comprised of patients, according to the recent revised criteria for probable dlb . exclusion criteria: * major psychiatrics disorders, depression
"association of proteinuria and progression of kidney dysfunction in sickle cell disease"disease

Conditions: Change in Albumin to Creatinine Ratio and Glomerular Filtration Rate; Progression of Kidney Failure and or All-cause Mortality

Summary: to describe change in acr and egfr during study follow-up, and assesss the association of baseline and change in acr and egfr, with progression of kidney failure and/or all-cause mortality.

this is a retrospective, non-interventional, secondary use of the data coming from the single-center secondary gen-mod study cohort at the henri mondor hospital (creteil, france). the gen-mod cohort includes 355 scd patients. the gen-mod data are accessible through the center's clinical and laboratory database and will be extracted and analyzed for the purpose of this study. the enrolment in the gen-mod cohort lasted from 01 december 2002 until 01 march 2014. follow-up occurred every six months and ranged from five to seventeen years and ended on 31 december 2019. the index date (baseline) for this study is the time of inclusion of patients in gen-mod cohort study

Eligibility criteria:
inclusion criteria: * adults aged ≥ 18 years old. * confirmed diagnosis of scd by hb electrophoresis or high performance liquid chromatography. scd genotypes hbss, hbsβ0-thal. * availability of acr and egfr baseline records. exclusion criteria: * patients enrolled in a chronic transfusion program. * patients receiving hydroxyurea treatment at the time of study enrollment.